Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Opdivo approved in Japan for relapsed or refractory classical Hodgkin's lymphoma

Dec. 5, 2016

FDA accepts for review sBLA for Keytruda in classical Hodgkin's lymphoma

Dec. 5, 2016

Bristol-Myers Squibb initiates phase I/IIa study of BMS-986207

Dec. 5, 2016

Dosing begins in phase I/II study of Agenus' INCAGN-1949

Dec. 2, 2016

First phase Ia/b data for anti-RSPO3 antibody OMP-131R10 in advanced solid tumors

Dec. 2, 2016

Daiichi Sankyo's DS-8201 given FDA fast track designation

Dec. 2, 2016

A first-in-class small-molecule inhibitor of PD-L1 and TIM-3

Dec. 2, 2016

FDA clears IND for KN-035

Dec. 1, 2016

Preclinical data on RG-7386 in solid tumors

Dec. 1, 2016

OncoQuest reports promising interim data from phase IIb study of oregovomab in ovarian cancer

Nov. 30, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 1, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...